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Massive hepatic angiomyolipoma in a young woman with
tuberous sclerosis complex: Signiﬁcant clinical improvement
during tamoxifen treatmentq
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5Pediatric Neurology Unit, Tor Vergata University, Rome, ItalyBackground/Aims: Isolated liver angiomyolipomas (AMLs) occur in about 40% of TSC patients. Because of their slow
growth, these tumors are often asymptomatic. Since AMLs express estrogen and progesteron receptors we suggest the
possible beneﬁts of tamoxifen for the treatment of liver AMLs.
Methods:We report the case of a 26-year-old female aﬀected by tuberous sclerosis (TSC2) with cerebral, renal and
hepatic involvement admitted to the Liver Unit for severe malnutrition, anorexia and abdominal pain. MRI showed a
grossly enlarged liver, causing severe gastric compression. The liver was entirely ﬁlled with multiple nodular lesions of dif-
ferent sizes. Liver biopsy showed tumoral tissue with microscopic and ultrastructural features of angiomyolipoma. All liver
function tests were repeatedly normal. Prior to considering the patient for partial hepatectomy, she was administered
tamoxifen (20 mg b.i.d).
Results:After 6 months of tamoxifen treatment a greatly improved quality of life and a signiﬁcant weight gain were
observed. After 12 months the clinical conditions further improved and the MRI showed a signiﬁcant reduction of the larg-
est lesion with a liquid central area and a diminished compression of the stomach.
Conclusions:This is to our knowledge the ﬁrst report in which tamoxifen has been successfully used in a TSC patient
with multiple liver angiomyolipomas.
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sclerosis.1. Introduction
Tuberous sclerosis (TSC) is a genetic, multisystemic
disorder characterised by widespread hamartomas with
cerebral, cardiac, cutaneous, ocular, renal, pulmonary,
and hepatic involvement [1,2]. The disorder has a birth
incidence of 1:6000 [3].
TSC has an autosomal dominant pattern of inheri-
tance, although two-thirds of all cases result from spo-
radic mutations. Multigenerational family analysis ofPublished by Elsevier B.V. All rights reserved.
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encoding, respectively, for hamartin and tuberin.
The hamartin–tuberin complex inhibits the mamma-
lian target of rapamycin (mTOR) that controls cell
growth and proliferation. mTOR detects signal of nutri-
ent availability, hypoxia or growth factor stimulation
[6,7]. This pathway is activated by estrogens (17b-estra-
diol), via tuberin and the small GTPase Ras homologue,
thus explaining the greater predisposition to tumours in
women than in men [8].
Multiple, bilateral angiomyolipomas are the most
common renal ﬁnding appearing in about 70–90% of
adult patients, and are more often symptomatic in
women [9,10]. They are composed of abnormal blood
vessels, smooth muscle and adipose tissue, and have
an immunoreactivity for HMB-45 (Human Melanoma
Black). Occasionally angiomyolipomas may involve
the liver, yet multiple hepatic lesions are extremely rare
and usually seen in patients with fully expressed TSC
[11,12]. We report on a female patient with TSC and
massive multiple liver and renal angiomyolipomas,
who experienced a remarkable clinical improvement
with long-term tamoxifen treatment, associated with
tumour size reduction and improved quality of life.2. Case history
A 26-year-old female with a clinical and molecular
diagnosis of TSC was admitted in June 2005 to the Liver
Unit for severe malnutrition, anorexia, nausea, and
abdominal pain. At the age of two years the patient
experienced generalized seizures and a clinical diagnosis
of tuberous sclerosis was made, in the presence of cere-
bral, renal, and hepatic involvement. DNA testing con-
ﬁrmed the mutation on chromosome 16 (exon 39). AnFig. 1. T2-weighted axial MRI of the upper abdomen performed before startin
VIII (A); axial MRI, performed after 12 months of tamoxifen treatment, reve
central area (B). [This ﬁgure appears in colour on the web].anti-epileptic treatment with vigabatrin was adminis-
tered with seizure remission until 12 years of age, when
focal motor seizures appeared. Lamotrigine and succes-
sively levetiracetam were started with partial seizure
control. Brain MRI showed cortical tubers, multiple
subependymal nodules, giant cell astrocytoma, radial
bands, and multiple cystic areas on the white matter.
The IQ value was normal, and awake and sleep EEG
recordings did not reveal epileptic abnormalities.
At that time the patient experienced nausea, anor-
exia, epigastric pain and severe malnutrition. When
she was 22 years old, her quality of life progressively
worsened and at the age of 26 she was referred to our
hospital for a clinical evaluation.
Abdominal MRI showed multiple diﬀuse angiomyo-
lipomas and cystic formations in both kidneys. The liver
was grossly enlarged (longitudinal diameter = 30 cm),
with the left lobe occupying the mid and left abdomen,
causing severe gastric compression. T1-weighted
dynamic sequences after gadolinium administration
showed multiple, nodular, hypointense and non-homo-
geneous lesions of diﬀerent sizes. The largest one (diam-
eter = 12 cm) was located between segment VII and VIII
(Fig. 1, panel A). Echo-guided percutaneous liver biopsy
revealed tumoral tissue with microscopic and ultrastruc-
tural features of angiomyolipoma. Upper gastrointesti-
nal endoscopy disclosed a surface gastritis associated
with two inﬂammatory polyps in the stomach.
The patient’s body weight was 50 kg, body mass
index was 19 and waist abdominal circumference was
90 cm. All liver function tests were repeatedly normal.
Neither previous pregnancies nor estrogen replace-
ment therapy were reported. An oral treatment with
tamoxifen, an anti-estrogen drug, was started (20 mg
b.i.d). After 3 months of treatment, the patient experi-
enced a signiﬁcantly improved quality of life associatedg tamoxifen showing a large focal area between liver segments VII and
aling a signiﬁcant reduction of the largest lesion with an enlarged liquid
Fig. 2. Eosinophilic epithelioid cells with focal nuclear positivity for estrogen receptors (ER) (A); cytoplasmic granular positivity for HMB45.
Eosinophilic epithelioid cells positive for vimentin and smooth muscle actin (B). [This ﬁgure appears in colour on the web].
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volumetric reduction of many hepatic lesions. There-
fore, oral tamoxifen was continued at the same dose
without interruption. After 6 months of treatment,
weight gain was 4 kg, and clinical conditions continued
to improve, with the recovery of well-being and appetite.
After 12 months of treatment, weight increase was 6 kg
and waist abdominal circumference was reduced from
90 to 83 cm. Abdominal MRI control revealed a signif-
icant reduction of the largest lesion, with an enlarged
liquid central area (Fig. 1, panel B). Moreover, liver size
and stomach compression were reduced due to fewer
and smaller liver lesions. Neither cerebral lesions nor
renal angiomyolipomas were signiﬁcantly improved.3. Histological analysis
Histological analysis was performed in formalin-
ﬁxed, paraﬃn-embedded liver biopsy tissue by conven-
tional methods. The liver showed diﬀuse inﬁltration by
clusters of smooth-like muscle cells, numerous scattered
adipocytes, often grouped, thick-walled blood vessels
and capillaries, associated to inﬂammatory cells, includ-
ing small lymphocytes, plasma cells, and histiocytes.
The smooth-like muscle cells consisted of spindle-
shaped cells or larger rounded cells with clear cytoplasm
and eosinophilic epithelioid cells. The immunohisto-
chemical analysis was performed in 4–6 lm sections of
liver biopsy specimens, using the avidin–biotin complex
(ABC) method. Angiomyolipoma spindle, rounded and
epitheliod cells were positive for smooth muscle actin
(Dako) and vimentin (Dako). Adipose cells were posi-
tive for S-100 protein (Dako). Pancytocheratin were
negative. The estrogen (ER) and progesterone (PR)
receptor analysis was performed using monoclonal anti-
body against ER (mouse anti-human estrogen receptor,clone 1D5-IgG1, Ylem) and PR (mouse anti-human
progesterone receptor, clone 1A6-IgG1, Ylem), showing
ER nuclear positivity focally restricted to angiomyoli-
poma epithelioid and clear cells (Fig. 2, panel A), and
PR negativity. Liver sections were also investigated for
the presence of HMB45 reactivity (Mouse anti-human
melanosome, clone HMB45, isotype IgG1 Kappa,
Dako) (Fig. 2, panel B).4. Discussion
As the incidence of TSC-related lesions increases
with age, hepatic hamartomas are more common in
adults, being reported in 23–45% of cases [13,14] with
a higher frequency in females. They do not usually
cause hepatic dysfunctions, and are mostly found inci-
dentally or during periodic follow-up studies. Only few
symptomatic hepatic hamartomas have been reported,
presenting with ﬂank pain, spontaneous haemorrhage
or rapid growth [15,16]. In contrast to renal lesions,
hepatic angiomyolipomas grow more slowly and are
not mentioned as a possible cause of death in TSC
patients [17].
Nowadays, the pathogenesis of angiomyolipomas is
still nearly unknown and, currently, no speciﬁc pharma-
cological treatments have been reported. A beneﬁcial
eﬀect of rapamycin on renal angiomyolipomas [18,19]
and subependymal giant cell astrocytomas [20] has been
reported in several studies, suggesting that rapamycin
(an inhibitor of mTOR pathway) or its analogues may
be eﬀective in the treatment of various TSC manifesta-
tions: e.g., lymphangioleiomyomatosis [21], renal angio-
myolipomas [22], renal cell carcinoma [23], or even in
reversing polycystic kidney disease [24].
Recently, El-Hashemite et al. [25], through analysis
of Tsc1+/ mice, proved the importance of estrogen
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suggesting possible beneﬁts of tamoxifen therapy in
angiomyolipomas and lymphangioleiomyomatosis.
These experimental observations prompted us to
explore in our young patient the clinical eﬀectiveness
of tamoxifen, a widely used drug in humans for the pre-
vention and the treatment of estrogen-related cancer
with few side-eﬀects.
The patient, initially referred to evaluate the possibil-
ity of partial hepatic resection, due to the high degree of
gastric compression, showed signiﬁcant clinical
improvement in terms of nutritional status and quality
of life, already evident after the initial months of treat-
ment. This improvement became remarkable and sus-
tained over time, with reduced size of liver
angiomyolipomas, including their partial necrotic invo-
lution, and until now has delayed surgical intervention.
Since in the literature tamoxifen has been reported to
cause steatohepatitis [26,27], a close monitoring of liver
function tests and routine ultrasounds are constantly
required.
This is to our knowledge the ﬁrst report in which
tamoxifen has been successfully used in a TSC patient
with multiple liver angiomyolipomas.
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